ArticleFrontiers in immunology2019
Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Complement factor H in cancer biology: intracellular functions, tumor-host interactions, and systemic context.Frontiers in immunology · 2026Review
- Review
- The complement regulator CD55 modulates TLR9 signaling and supports survival in marginal zone B cells.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- A genome-wide association study in 10,000 individuals links plasma N-glycome to liver disease and anti-inflammatory proteins.Nature communications · 2025Article
- Identification of CFH and FHL2 as biomarkers for idiopathic pulmonary fibrosis.Frontiers in medicine · 2024Article
- Complement factor H: a novel innate immune checkpoint in cancer immunotherapy.Frontiers in cell and developmental biology · 2024Review
- The human factor H protein family - an update.Frontiers in immunology · 2024Review
- Study on gene expression in the liver at various developmental stages of human embryos.Frontiers in cell and developmental biology · 2024Article
- Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis.Immunity · 2023Article
- Dysregulation of miR-146a: a causative factor in epilepsy pathogenesis, diagnosis, and prognosis.Frontiers in neurology · 2023Review
- Effect of Heme Oxygenase-1 Depletion on Complement Regulatory Proteins Expression in the Rat.Antioxidants (Basel, Switzerland) · 2022Article
- A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in RatsFrontiers in immunology · 2022Article
- Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy.International urology and nephrology · 2021Article
- Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice.Frontiers in immunology · 2021Article
- Homodimeric Minimal Factor H:Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Complement factor H (CFH) has a pivotal role in regulating alternative complement activation through its ability to inhibit the cleavage of the central complement component C3, which links innate and humoral immunity. However, insights into the role of CFH in B cell biology are limited. Here, we demonstrate that deficiency of CFH in mice leads to altered splenic B cell development characterized by the accumulation of marginal zone (MZ) B cells. Furthermore, B cells in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.